Yet as clinical use grows, so does interest in how GLP1 medications affect skeletal health particularly their impact on bone density, remodeling, and fracture risk
The table below lists the adverse events that have been reported in two double-blind, placebo- controlled trials in patients on chronic hemodialysis
So that should be priority number one for anyone, whether its a policymaker, and a healthcare professional, or an insurer or pharmacy benefit manager or a patient group to address because unless we address that everything else falls apart
Support is generally strong
Perhaps it was just a matter of time before we made it official
however, we will not submit prior-authorization paperwork for people without diabetes or pre-diabetes (pre-diabetes is occasionally, but usually not covered)